Dasatinib and Quercetin for Older Adults With Secondary Progressive Multiple Sclerosis
Tests dasatinib and quercetin in older adults with secondary progressive multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Senolytics for Secondary Progressive MS
Key facts
- Where
- Columbus, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT07270120, who can take part
Where in United States
- Ohio State Martha Morehouse Outpatient CareColumbus, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ohio State University
- Trial code
- NCT07270120
- Record updated
- 8 December 2025
- Original description
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.Read full original descriptionShow less
Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.
Inclusion: Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria; Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone; Evidence of MS progression over the past 12 months.
Exclusion: Drug or alcohol abuse in the previous 5 years; Use of drugs metabolized by the same liver enzymes as D or Q; Unstable coronary artery disease (myocardial infarction within 6 months or angina); Stroke or transient ischemic attack in the past 6 months; Pulmonary arterial hypertension; Current or chronic history of liver disease; Alzheimer's or Parkinson's disease; History of coagulation disorders, central nervous system hemorrhage, or gastrointestinal hemorrhage; History of angina or myocardial infarction, arrhythmia, or heart failure at any time; Chronic renal disease (glomerular filtration rate < 30 mL/min/1.73 m2); QTc prolongation; Anemia (Hgb<9), thrombocytopenia (platelets<50,000 per microliter), or neutropenia (ANC< 1000 per microliter); Moderate hypokalemia (2.9 mmol/L) and moderate hypomagnesemia (0.9-1.1 mg/dL or 0.37-0.45 mmol/L); ALT/AST >1.5x ULN, total bilirubin >ULN, and alkaline phosphatase >2x ULN; Anti-arrhythmic medications known to cause QTc prolongation; Anti-platelet or anti-coagulant medications other than aspirin; Hospitalization within 6 months; Alcohol intake greater than 2 drinks/day for men and greater than 1 drink/day for women; Antipsychotics and anxiolytics; Quinolone antibiotics; Pregnant or lactating subjects or subjects intending to become pregnant or to donate egg/sperm; Participants with p16INK4a below the median of SPMS patients in the OSU Aging and MS Cohort.